Exploratory post hoc pooled analysis of phase I and II trials in 171 patients with EGFR-mutated NSCLC progressing on EGFR TKIs: iza-bren showed confirmed ORR 47.4%, median PFS 6.9 months and median OS 24.8 months; grade ≥3 treatment-related AEs 70.2%.
Meta-analysisn = 171
Hong et al. Izalontamab brengitecan (Iza-bren; BL-B01D1), a first-in-class EGFR-HER3 bispecific antibody-drug conjugate, for patients with EGFR-mutated NSCLC: pooled analysis of phase I and phase II trials